BMI View: Norway’s 2016 fiscal stimulus is expected to be positive in terms of supporting the
pharmaceutical and healthcare sector growth trajectory. Over the long term, policies aimed at promoting
economic diversification away from energy exports are set to benefit the biotech and pharmaceutical sector
development, which will remain a key policy priority. A growing and ageing population and high per capita
expenditure on medicine will ensure renewed opportunities for drugmakers over the forecast period despite
the small market size.
Headline Expenditure Projections
Pharmaceuticals: NOK21.70bn (USD3.48bn) in 2014 to NOK21.98bn (USD2.69bn) in 2015; +1.28% in
local currency terms and -22.9% in US dollar terms. Forecast broadly in line with last quarter.
Healthcare: NOK298.21bn (USD47.86bn) in 2014 to DKK308.59bn (USD38.72bn) in 2014; +3.5% in
local currency terms and -21.2% in US dollar terms. Forecast revised slightly downwards from last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Norway 2013-2019) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2011-2019) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019) 19
Prescription Drug Market Forecast 20
Pharmaceutical Trade Forecast 23
Table: Pharmaceutical Trade Data And Forecasts (Norway 2013-2019) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2013-2019) 25
Industry Risk/Reward Index 26
Western Europe Risk/Reward Index 26
Norway Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Pricing Regime 36
Reimbursement Regime 37
Market Overview 40
Healthcare Sector 41
Table: Healthcare Resources (Norway 2009-2014) 42
Table: Healthcare Personnel (Norway 2009-2014) 42
Table: Healthcare Activity (Norway 2009-2014) 43
Research and Development 43
Clinical Trials 45
Epidemiology 45
Competitive Landscape 47
Table: The Top 25 Pharmaceutical Companies In Norway 48
Table: Multinational Market Activity 50
Demographic Forecast 52
Table: Population Headline Indicators (Norway 1990-2025) 53
Table: Key Population Ratios (Norway 1990-2025) 53
Table: Urban/Rural Population & Life Expectancy (Norway 1990-2025) 54
Table: Population By Age Group (Norway 1990-2025) 54
Table: Population By Age Group % (Norway 1990-2025) 55
Glossary 57
Methodology 59
Pharmaceutical Expenditure Forecast Model 59
Healthcare Expenditure Forecast Model 59
Notes On Methodology 60
Risk/Reward Index Methodology 61
Index Overview 62
Table: Pharmaceutical Risk/Reward Index Indicators 62
Indicator Weightings 63

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Norway 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Norway 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2013-2019)
Table: Healthcare Resources (Norway 2009-2014)
Table: Healthcare Personnel (Norway 2009-2014)
Table: Healthcare Activity (Norway 2009-2014)
Table: The Top 25 Pharmaceutical Companies In Norway
Table: Multinational Market Activity
Table: Population Headline Indicators (Norway 1990-2025)
Table: Key Population Ratios (Norway 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Norway 1990-2025)
Table: Population By Age Group (Norway 1990-2025)
Table: Population By Age Group % (Norway 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators